{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-068597","form_type":"8-K","ticker":"UNCY","cik":"0001766140","company_name":"Unicycive Therapeutics, Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.456753+00:00","generated_at":"2026-05-31T09:22:56.545318+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Unicycive Q2 net income $3.0M; OLC NDA on track for August 2024","bullets":["OLC pivotal trial: 1.4% discontinuation rate (evaluable) for treatment-related AEs; no SAEs.","Patient survey: 79% preferred OLC, 98% found it easy to take, 89% satisfied.","UNI-494 Phase 1 enrollment completed; data expected Q3 2024; new patent granted until 2040.","R&D expenses $4.9M (up $2.6M YoY); cash $41.8M, sufficient into 2026.","Diluted EPS loss $0.15; basic EPS $0.08 due to warrant liability fair value change."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-068597","json":"https://secwatch.observer/filing/0001213900-24-068597.json","markdown":"https://secwatch.observer/filing/0001213900-24-068597.md","text":"https://secwatch.observer/filing/0001213900-24-068597.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1766140/000121390024068597/0001213900-24-068597-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1766140/000121390024068597/ea0211321-8k_unicycive.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:22:56.545318+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}